Purpose: A fast-rotating O-ring dedicated intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) delivery system, the Halcyon, is delivered by default with a fully preconfigured photon beam model in the treatment planning system (TPS). This work reports on the validation and achieved IMRT/VMAT delivery quality on the system. Methods: Acceptance testing followed the vendor's installation product acceptance and was supplemented with mechanical QA. The dosimetric calibration was performed according to the IAEA TRS-398 code-of-practice, delivering 600 cGy/min at 10 cm depth, a 90 cm source-surface distance, and a 10 9 10 cm² field size. The output factors, multileaf collimator (MLC) transmission and dosimetric leaf gap (DLG) were validated by comparing measurements with the modeled values in the TPS. Validation of IMRT/VMAT was conducted following AAPM reports (MPPG 5.a, TG-119). Next, dose measurements were performed for end-to-end (E2E) checks in heterogeneous anthropomorphic phantoms using radiochromic film in multiple planes and using ionization chambers (IC) point measurements. E2E checks were performed for VMAT (cranial, rectum, spine, and head and neck) and IMRT (lung). Additionally, IROC Houston mailed dosimetry audits were performed for the beam calibration and E2E measurements using a thorax phantom (IMRT) and a head and neck phantom (VMAT). Lastly, extensive patient-specific QA was performed for the first patients of each new indication, 26 in total (n rectum = 2, n spine = 5, n lung = 5, n esophagus = 2, n head and neck = 7, n cranial = 5), treated on the fast-rotating O-ring linac. The patient-specific QA followed the AAPM TG-218 guidelines and comprised of portal dosimetry, ArcCHECK diode array, radiochromic film dosimetry in a MultiCube phantom, and IC point measurements. Results: The measured output factors showed an agreement <1% for fields ≥3 9 3 cm². Field sizes ≤2 9 2 cm² had a difference of <2%. The measured single-layer MLC transmission was 0.42 AE 0.01% and the measured DLG was 0.27 AE 0.22 mm. The AAPM MPPG 5.a measurements were fully compliant with the guideline criteria. Dose differences larger than 2% were found for the PDD at large depths (>25 cm). TG-119's confidence limits were achieved for the VMAT point dose measurements and for both the IMRT and VMAT radiochromic film measurements. The TG-119 confidence limits were not achieved for IMRT point dose measurements in both the target (5.9%) and the avoidance structure (6.4%). All E2E tests had point differences below 2.3% and gamma agreement scores above 90.6%. The IROC beam calibration audit showed agreement of <1%. The IROC lung IMRT audit and head and neck VMAT audit had results compliant with the IROC Houston's credentialing criteria. All IMRT and VMAT plans selected for patient-specific QA were within the action limits suggested by TG-218. Conclusions: The fast-rotating O-ring linac and its preconfigured TPS are compliant with the international commissioning criteria of AAPM MPPG 5.a and AAPM TG-119. E2E measurements on heterogeneous anthropomorphic phantoms were within clinically acceptable tolerances. IROC Houston's audits satisfied the credentialing criteria. This work comprises the first extensive dataset reporting on the preconfigured fast-rotating O-ring linac.
INTRODUCTION
The use of intensity modulated radiotherapy (IMRT) 1 and volumetric modulated arc therapy (VMAT) 2 for the treatment of cancer has been growing continuously over the past decade. [3] [4] [5] The highly conformal dose distributions to targets, while sparing organs at risk (OAR), have led to improvements in clinical outcome for multiple indications. [6] [7] [8] However, the safety and efficacy of IMRT/VMAT treatments can only be assured if the treatment planning system (TPS) is commissioned adequately. [9] [10] [11] Conventionally, IMRT/VMAT commissioning consists of multiple steps, starting with beam data acquisition supplemented with additional measurements for the modeling of small beam apertures and multileaf collimator (MLC) parameters characteristic for IMRT/VMAT delivery. 12, 13 Such small-field measurements are challenging and require careful measurement setup and the use of appropriate detectors as pointed out by the IAEA TRS-483 code-of-practice (CoP). 14 Subsequently, the collected data are used in an iterative process of fine-tuning and validating the photon beam models in the TPS (e.g., AAPM MPPG 5.a 15 ). As a final step, beam model validation should be supplemented with IMRT/VMAT validation tests (e.g., AAPM TG-119 16 ), end-to-end testing (E2E), and external mailed audits. [17] [18] [19] Hence, commissioning of IMRT/VMAT is a long and labor-intensive endeavor.
To reduce the commissioning workload, vendors offer the possibility to match the system with respect to a reference beam model, referred to as "Golden beam data", encompassing most or all of the commissioning beam data required by the TPS. Certain systems, such as the TomoTherapy system, 20 are delivered by default with a preconfigured TPS already containing the reference beam model. However, the performance of preconfigured systems depends on the reproducibility of the manufacturing procedures of the linac system and can be affected by on-site changes made during installation. 12 In this regard, the commissioning of a preconfigured system needs to validate whether the installed system and the reference beam model are within the commissioning criteria and do not need any on-site modifications to satisfy these criteria.
A fast-rotating O-ring dedicated IMRT/VMAT delivery system, Halcyon (Varian Medical Systems, Palo Alto, CA, USA), is delivered by default with a fully preconfigured photon beam model in the TPS. At the moment, little data are available on the performance of the system with respect to its accompanying preconfigured TPS and the IMRT/VMAT delivery quality. Additionally, it is not yet known to what extent on-site adjustments are necessary in order for the system to satisfy the commissioning criteria.
For this purpose, this work reports on the validation and achieved treatment delivery quality of IMRT/VMAT on the preconfigured fast-rotating O-ring linac. International guidelines were used to benchmark the performance of the system and multiple validation tests of increasing complexity were performed. The preconfigured photon beam model was validated using AAPM MPPG 5.a validation tests. 15 IMRT/ VMAT delivery techniques and the photon optimizer (PO) were validated using the AAPM TG-119 test cases. 16 Additionally, E2E measurements on heterogeneous anthropomorphic phantoms and external mailed E2E audits (IROC Houston thorax phantom 17 and head and neck phantom 18, 19 ) were performed. Finally, extensive patient-specific quality assurance (QA) was performed for the first patients of each new indication treated on the system. This work comprises the first extensive dataset reporting on the preconfigured fastrotating O-ring linac, offering reference information for future users of the system.
MATERIALS AND METHODS
An overview of all the validation tests performed in this manuscript is given in Table S1 together with the utilized measurement equipment for each test.
2.A. Fast-rotating O-ring linac and preconfigured TPS
The Halcyon TM IMRT/VMAT delivery system (Varian Medical Systems) consists of a single-energy 6 MV flattening filter free (FFF) straight-through linac mounted on an encapsulated fast-rotating O-ring gantry. The encapsulated O-ring design allows for a maximum gantry speed of 4 rpm. The maximum field size (28 9 28 cm² at isocenter) is outlined by a jawless dual-layer MLC. The MLC is composed of 29 proximal leaf pairs (upper bank) and 28 distal leaf pairs (lower bank). Two additional distal leaf pairs outline the maximum field size. The proximal leaves are offset by 5 mm from the distal leaves, such that the tongue and groove region of the proximal leaves are blocked by the distal leaves and vice versa. The MLC leaves have a projected leaf width of 10 mm at the isocenter, a maximum leaf speed of 5 cm/s and a leaf span of 28 cm. Field shaping is performed by the distal leaves only, whereas the proximal leaves serve as backup jaw. On the opposite site of the gantry ring, an electronic portal imaging device (EPID) is mounted on top of a beam stopper. The EPID has a field-of-view (FOV) of 43 9 43 cm² with a 0.34 9 0.34 mm² in-plane pixel size and has a 154 cm source-imager-distance (SID). To support a swift patient positioning, the system has an embedded laser positioning system. Daily online MV imaging for patient setup is performed using either orthogonal anterior-posterior/lateral pairs (MV-MV) or MV cone-beam computed tomography (MV-CBCT) each with "Low-Dose" and "High-Quality" modes. 21 The system is delivered with a fully preconfigured photon beam model for the Anisotropic Analytical Algorithm (AAA) and PO in the Eclipse (v15.1) TPS (Varian Medical Systems). Only the dosimetric calibration can be modified by the user.
2.B. Acceptance testing and mechanical quality assurance
Acceptance testing followed the vendor's installation product acceptance (IPA) and was supplemented with mechanical QA and patient-specific QA for a complex IMRT and VMAT test case. The IPA comprised a dose rate stability vs gantry rotation check, which verifies whether the dose rate remains stable to within AE7% during a full gantry rotation of 360°. Subsequently, the radiation isocenter and position accuracy verification was performed using the dedicated machine performance check (MPC) and Drum phantom (Varian Medical Systems), which comes delivered with the preconfigured system. The MPC is an automated set of QA tests to verify beam constancy and mechanical performance of the linac by analyzing MV images acquired at various machine positions, with and without the Drum phantom. 22, 23 The initial MPC values were set as baseline for future daily QA measurements. The beam energy and symmetry was validated using the Blue Phantom² (IBA, Louvain-La-Neuve, Belgium), a FC-65G Farmer (IBA) ionization chamber (IC) and a PC Electrometer TM (Sun Nuclear, Melbourne, FL, USA). The depth of maximum dose should be at 1.3 AE 0.2 cm and the relative dose deposited at 10 cm depth should be 63.0 AE 1.0% with respect to the maximum dose. The symmetry is defined as the maximum variation in integrated dose between corresponding points equidistant from the beam centerline (IEC definition 24 ) and should be within 2% for a 28 9 28 cm² open field. The dose reproducibility with respect to MU (500, 1000 and 1500 MU) and gantry angle (90°, 270°and 0°) was verified using the same setup and should be within 1%. MV imaging contrast was verified using the Las Vegas phantom. 25 Mechanical QA followed the AAPM TG-142 report using IMRT machine-type tolerances. 26 Gantry and collimator star shots (measured at both 0°and 90°gantry angle) were performed using radiochromic RTQA2 film (Ashland Specialty Ingredients, Wayne, NJ, USA) following the method by Depuydt et al. 27 Dosimetry integration for patient-specific QA with the EPID was validated using two sliding window IMRT test patterns: a chair and a pyramid. 28 Patient-specific QA was performed for a preselected complex IMRT and VMAT treatment plan using the EPID and an ArcCHECK TMdiode array (Sun Nuclear, Melbourne, Australia) as a first check of the IMRT/VMAT delivery quality on the preconfigured system. The evaluation was performed using 3%(local)/ 3 mm gamma analysis 29 using a low-dose exclusion threshold set to 10% of the maximum dose.
2.C. Dosimetric calibration
Absolute dose calibration followed the IAEA TRS-398 30 code-of-practice. Dose output was calibrated as 1 cGy/MU delivered to water at 10 cm reference depth (d ref ) and 90 cm source-surface distance (SSD) with a 10 9 10 cm² reference field size. The dose rate at d ref was 600 cGy/min. Dose measurements were performed in a Blue Phantom² using a FC-65G IC and a PC Electrometer TM . The SSD of the water surface and IC setup were checked using MV x-ray imaging as there was no light field due to the encapsulated O-ring design. The SSD is checked by an MV x-ray image at a 84.3°g
antry angle for which the water surface will project onto a sharp edge at 10 cm distance from the beam's central axis in the projection image. The position of the IC was checked using orthogonal MV x-ray images at 0°and 90°gantry angle and manual alignment with respect to the beam's central axis.
2.D. Basic photon beam model validation

2.D.1. Field output factors
Field output factor measurements were performed in the Blue Phantom² at d ref (10 cm) with 90 cm SSD. In accordance with the IEAE TRS-483 CoP, 14 a CC13 IC (IBA) was used as large field detector (field size ≥ 4 9 4 cm²) and a PinPoint 3D IC (PTW, Freiburg, Germany) was used as small-field detector (field size ≤ 4 9 4 cm²). Small-field output factors were determined using the daisy chaining technique 31 with an intermediate field size of 4 9 4 cm². Output correction factors for the PinPoint 3D IC were extracted from TRS-483.
14 Field output factors were relative with respect to a 10 9 10 cm² reference field.
Measured field output factors were compared with field output factors calculated by the preconfigured TPS. These were determined by calculating the dose in a simulated water phantom (65 9 65 9 40 cm³) using AAA 15.1.51 (dose grid size: 1 9 1 9 1 mm³) for the various field sizes.
2.D.2. Validation of MLC parameters
The AAA beam model uses two parameters to model the MLC: the leaf transmission per layer and the dosimetric leaf gap (DLG). The DLG models the partial transmission through the rounded leaf edges of the MLC (234 mm radius of curvature). 32, 33 The DLG was determined for the distal leaves using the sweeping gap technique 32 with the distal leaves open, closed, and dynamic sweeping gaps from 2 to 20 mm in 2 mm increments. The MLC transmission was determined for each leaf bank individually as part of the DLG measurements. Measurements were performed in a water-equivalent acrylic cylindrical phantom (Ø = 20 cm) using a FC-65G Farmer IC.
Calculation of the DLG used the method of LoSasso et al. 32 Collected charges were corrected for the MLC transmission by subtracting the charge collected for the field with closed distal MLC. The DLG was subsequently calculated as the intersection between the horizontal axis and the linear extrapolation of the corrected charges for the different sweeping gaps.
2.D.3. Validation of static fields in nonstandard conditions
The AAPM MPPG 5.a report 15 suggests a number of validation tests to be performed for static fields in nonstandard conditions. 34 A summary of the validation tests performed in this study is given in Table S1 . Percent depth dose (PDD) and dose profiles (both inline and crossline) were measured using a CC13 IC (MPPG 5.a tests 5.3-5.8) or a PinPoint 3D IC (MPPG 5.a tests 7.1-7.2) in the Blue phantom² (scanning volume: 48 9 48 9 41 cm³). Dose profiles were measured at 1.26 cm (d max ), 5 cm, 10 cm, and 20 cm depth. Measurements were performed step by step using equidistant steps of 2 mm with an in-scan position speed of 2 mm/s and a 1 s integration time. All measurements were processed using the myQA Accept v8.2.7 software (IBA).
Radiochromic EBT3 film (Ashland Specialty Ingredients) was used as a second detector for tests 5.5, 5.6, 5.8, 7.1, and 7.2. The high spatial resolution of radiochromic films (inplane resolution of 0.17 9 0.17 mm²) allowed to investigate the penumbra in more detail without the concern of volume averaging effects. The EBT3 films were positioned in a stack (dimensions: 40 9 40 9 20 cm³) of water-equivalent RW3 (PTW) at 10 cm depth. Dose conversion of the EBT3 films used an in-house developed calibration protocol 35 and triplechannel dose conversion 36 implemented in MeVisLab v2.5 (MeVis Medical Solutions AG, Bremen, Germany).
Measured PDDs and dose profiles of the test cases were compared with the dose calculated in a simulated water phantom (65 9 65 9 40 cm³) using AAA 15.1.51 (dose grid size: 1 9 1 9 1 mm³). Prior to comparison the dose profiles were normalized with respect to the prescribed dose (PD) at 10 cm depth. The PDDs and dose profiles were corrected for the effective point of measurement of the IC as postprocessing. The comparison was performed using the open-source Profile Comparison Tool 37 in Matlab R2017b (Mathworks, Natick, MA, USA). Evaluation was performed using a 1D gamma analysis on the PDD and dose profiles using 2%(local)/2 mm criteria and 3%(global)/3 mm criteria. The number of points that passed the criteria (c-index <1) was determined for the high dose region (dose points above 80% of the PD), the penumbra (dose points between 20% and 80% of the PD) and the low-dose tail (dose points below 20% of the PD) individually. A dose comparison was considered passing the gamma criteria if the gamma agreement score (cAS) was greater than 95%. A validation measurement passed the MPPG 5.a criteria if the high dose region passed the 2%(local)/2 mm gamma criteria and if both the penumbra and low-dose tail passed the 3%(global)/3 mm criteria. This is consistent with the MPPG 5.a tolerances of a 2% local dose difference in the high dose region, a 3 mm distance to agreement in the penumbra and a 3% dose difference with respect to the maximum dose in the low-dose tail.
2.E. IMRT/VMAT validation
Validation of IMRT and VMAT followed the AAPM TG-119 guidelines. 16 TG-119 consists of a set of test cases (multitarget, mock prostate, mock head and neck, C-shape easy and C-shape hard) to assess the overall accuracy of treatment planning and delivery of IMRT/VMAT. Dose measurements were performed using an A1SL IC (Standard Imaging, Middleton, WI, USA) with PC Electrometer TM and radiochromic EBT3 film in a stack (dimensions: 40 9 40 9 20 cm³) of water-equivalent RW3. Treatment plans were generated in Eclipse using the PO algorithm v15.1.51 (structure sampling resolution of 1.25 mm) and final doses were calculated using AAA 15.1.51 (dose grid size: 1 9 1 9 1 mm³).
Point IC measurements were compared with respect to the TPS using the median dose value over the active volume of the IC segmented on a CT-scan of the measurement setup. Film evaluation was performed using 3%(local)/3 mm gamma criteria 29 implemented in an in-house developed Matlab script. 38 A global rescaling of the film with respect to the TPS and a low-dose exclusion threshold set to 10% of the PD was utilized during gamma analysis. Confidence limits for both IC and film measurements were calculated according to TG-119. 16 
2.F. End-to-end testing on heterogeneous anthropomorphic phantoms
End-to-end (E2E) tests were performed for IMRT/VMAT using heterogeneous anthropomorphic phantoms from CIRS (CIRS, Norfolk, VA, USA). E2E measurements comprises:
• 2-arc rectum VMAT delivering 2 Gy to the dynamic pelvis phantom.
• 2-arc spine VMAT (both lumbar and dorsal vertebra) delivering 3 Gy to the E2E SBRT thorax phantom with abdomen section.
• 9-field lung IMRT delivering 2.75 Gy to the E2E SBRT thorax phantom with abdomen section.
• 3-arc head and neck VMAT delivering 2.2 Gy to the proton therapy dosimetry head phantom.
• 2-arc hippocampal-sparing cranial VMAT delivering 2.5 Gy to the proton therapy dosimetry head phantom.
Treatment plans were generated using PO v15.1.51 (structure sampling resolution of 2.5 mm) according to internal planning techniques. 39 Final dose calculation was performed using AAA v15.1.51 (dose grid size: 2.5 9 2.5 9 2.5 mm³).
Online positioning of the anthropomorphic phantom was performed using the internal lasers and a low-dose MV-CBCT. The imaging dose of the MV-CBCT is calculated using the Fourier Transform Dose Calculation (FTDC) algorithm (dose grid size: 5 9 5 9 5 mm³) and is incorporated in both plan optimization and the final dose calculation. Dose measurements were performed using the A1SL IC in multiple locations and using radiochromic EBT3 film in multiple planes. Radiochromic films were laser-cut using a Trotec laser cutter (Trotec Laser GmbH, Wels, Austria) to fit in the anthropomorphic phantoms. Data analysis was performed analogous to Section 2.E using 3%(local)/3 mm gamma criteria and a low-dose exclusion threshold set to 10% of the maximum dose for the radiochromic film measurements.
2.G. External mailed dosimetry audits
The output calibration performed in Section 2.B was validated with a mailed IROC Houston TLD dosimetry audit (Imaging and Radiation Oncology Core Houston Quality Assurance Center, http://rpc.mdanderson.org/rpc/). For IMRT and VMAT external mailed E2E audits were performed using the IROC Houston dynamic thorax phantom 17 (9-field IMRT, 29 3.0 Gy delivered to the target) and head and neck phantom 18, 19 (3-arc VMAT, 39 2.2 Gy delivered to the target). Dose measurements in both anthropomorphic phantoms were performed using TLDs and radiochromic films. Film analysis was performed by IROC Houston using 7%(global)/5 mm c-criteria.
2.H. Patient-specific quality assurance
Extensive patient-specific QA was conducted for the first patients of each new indication treated on the fast-rotating Oring linac during ramp-up, 26 in total (n rectum = 2, n spine = 5, n lung = 5, n esophagus = 2, n head and neck = 7, n cranial = 5). The dose prescription for each indication is given in Table S1 . The patient-specific QA encompassed portal image dosimetry using the integrated EPID, ArcCHECK TM diode array, radiochromic EBT3 film dosimetry in a MultiCube phantom (IBA) and point measurements in the MultiCube using the A1SL IC. Planar dose measurements were analyzed using 3%(local)/2 mm c-criteria and a low-dose exclusion threshold set to 10% of the maximum value in the plane as recommended by the AAPM TG-218 guidelines. 40 Global rescaling with respect to the TPS was performed for the film measurements prior to gamma analysis. Portal image dosimetry was evaluated for each treatment field or arc individually using identical c-criteria.
RESULTS
The preconfigured system was commissioned within 2 weeks after completion of the installation process and subsequent acceptance. The total time required on the machine to perform the measurements described in this study was 62 h. time dedicated to preparation and analysis of the measurements. Measurements were performed in teams of two medical physics experts.
3.A. Acceptance testing and mechanical quality assurance
The preconfigured system passed all verification checks included in the IPA. The measured depth of maximum dose was located at 1.3 cm (tolerance: 1.3 AE 0.2 cm) and the relative dose at 10 cm depth was 63.3% (tolerance: 63.0 AE 1%) with respect to the maximum dose. The symmetry (IEC definition 24 ) was 0.41% and 0.73% (tolerance: <2%) for inline and crossline profiles respectively. The dose reproducibility was below 0.1% with respect to MU and below 0.4% with respect to the gantry angle (tolerance: <1%). The gantry rotation isocenter size was 0.13 AE 0.03 mm, whereas the collimator rotation isocenter size was 0.09 AE 0.03 mm and 0.08 AE 0.03 mm for 0°and 90°gantry angle, respectively (tolerance: <1 mm). The complex IMRT and VMAT test cases had 3%(local)/3 mm cAS above 99% and 96% for EPID and ArcCHECK, respectively (clinical tolerance: ≥90%). Figure 2 (a) displays the measured and calculated field output factors. Deviations up to 2% were found between the measured and calculated field output factors for the smallest fields (1 9 1 cm² and 2 9 2 cm²), whereas field sizes ≥3 9 3 mm² had deviations <1%.
3.B. Basic photon beam model validation
The corrected charges for the different sweeping gaps are depicted in Fig. 2(b) . The DLG was determined to be 0.27 AE 0.22 mm (R² of linear fit was 0.999) compared to 0.10 mm as modeled in the preconfigured TPS. The MLC transmission through each leaf bank individually was 0.42 AE 0.01% compared to the modeled value of 0.47% in the TPS. Table I , summarizes the validation results of MPPG 5.a tests 5.4-5.8 and 7.1-7.2. The high-dose region passed the 2%(local)/2 mm gamma criteria, whereas both the penumbra and the low-dose tail passed the 3%(global)/3 mm gamma criteria. The PDD of tests 5.5, 5.8 and 7.2 showed dose differences larger than 2% at large depths (≥25 cm). The measured penumbra was less sharp compared to the calculation by the TPS (Fig. 3) . Radiochromic film measurements for tests 5.5, 5.6, 5.8, 7.1, and 7.2 showed good agreement between the measured and the predicted penumbra by the TPS (Fig. 3) .
FIG. 2. (a)
Displays the field output factors measured using the CC13 IC, the PinPoint 3D IC, and the calculated value for field sizes ranging from 1 9 1 cm² to 28 9 28 cm² (maximum field size). The inset displays the field output factors for small fields (≤4 9 4 cm²). (b) Visualizes the measured corrected charges for the different sweeping gaps and a linear fit (R² = 0.999) to determine the DLG according to the method by Losasso et al. 32 The intersection with the horizontal axis (0.27 AE 0.22 mm) is determined as the DLG. TABLE I. Percentage and absolute number within brackets of MPPG 5.a validation measurements that passed the gamma evaluation (cAS ≥ 95%) for the lowdose tail (dose points below 20% of the PD), the penumbra (dose points between 20% and 80% of the PD) and the high dose region (dose points above 80% of the PD). (8) 100% (8) 100% (8) 100% (8) 100% (8) 5.5 17 0% (0) 29% (5) 94% (16) 100% (17) 100% (17) 100% (17) 5.6 2 0% (0) 0% (0) 100% (2) 100% (2) 100% (2) 100% (2) 5.7 4 0% (0) 75% (3) 100% (4) 100% (4) 100% (4) 100% (4) 5.8 2 0% (0) 0% (0) 100% (2) 100% (2) 100% (2) 100% (2) 7.1 8 0% (0) 100% (8) 100% (8) 100% (8) 100% (8) 100% (8) 7.2 2 0% (0) 100% (2) 100% (2) 100% (2) 100% (2) 100% (2) Medical Physics, 46 (1), January 2019
This confirms that the measured penumbra for the scanning IC was less sharp due to volume averaging effects and that the reference beam model accurately predicts the penumbra. All validation measurements satisfied the MPPG 5.a tolerances. 15 Table II summarizes the point dose and radiochromic film measurements for the TG-119 test cases and the corresponding confidence levels for IMRT and VMAT. The obtained point dose confidence levels were 4.4% (target: 5.9%, avoidance structure 6.4%) for IMRT and 4.1% (target: 4.1%, avoidance structure: 4.5%) for VMAT. The c-criteria (3%(local)/3 mm) confidence levels for the radiochromic film measurements were 8.3% (target: 7.9%, avoidance structure: 2.8%) for IMRT and 3.9% (target: 7.6%, avoidance structure 4.4%) for VMAT. IMRT failed the recommended confidence levels of TG-119 16 for point dose measurements in both the target (5.9% vs 4.5%) and the avoidance structure (6.4% vs 4.7%). VMAT passed the recommended confidence levels for point dose measurements in both the target (4.1% vs 4.5%) and the avoidance structure (4.5% vs 4.7%). Both IMRT and VMAT passed the recommended confidence cm² open field at 30°oblique incidence. Note that the penumbra for the scanning IC profiles (dashed) was less sharp compared to the TPS calculations (gray) due to volume averaging whereas the penumbra for the radiochromic film measurements (dotted) coincided with the predicted penumbra. [Color figure can be viewed at wileyonlinelibrary.com] levels of TG-119 16 for radiochromic film measurements (tolerance: 12.4%) in both the target and the avoidance structure. Figure 4 , displays a representative set of E2E film measurements for IMRT (lung) and VMAT (spine, head and neck and cranial). The radiochromic film measurements had cAS (3%(local)/3 mm) of 94.2% (spine); 95.1% and 96.8% (lung, two planes); 94.1%, 93.8%, and 90.6% (head and neck, three planes); 96.3%, 92.6%, and 90.9% (cranial, three planes); and 99.8% (rectum). The point differences for the E2E tests were À1% (spine), À0.6% and À1.9% (lung, point dose measurement in primary tumor and spinal cord), À2.3% (head and neck), and À0.3% (cranial). All point dose measurements and all radiochromic film measurements were within clinically acceptable tolerances (i.e., point dose difference <3% and cAS ≥ 90%).
3.C. IMRT/VMAT commissioning
3.D. End-to-end testing
3.E. External mailed dosimetry audits
The IROC beam calibration audit showed an agreement of 1% between calculated and measured dose for the mailed TLD and was within the credentialing tolerance of 5%.
Both the lung IMRT audit and head and neck VMAT audit satisfied the IROC Houston's credentialing criteria. The IROC tolerance values are denoted within brackets for each measurement. The IROC lung IMRT audit had an agreement of À1% and À3% for the TLD located in the superior and inferior PTV, respectively (tolerance: ≤5%). The measured dose for the TLD located at the heart and the cord were both within the IROC Houston criteria. The average cAS (7%(-global)/5 mm) over the three film planes was 95% (tolerance: ≥85%). The individual cAS were 96.9%, 93.9%, and 93.1% for the axial, coronal, and sagittal film plane, respectively (tolerance: ≥80%).
The IROC head and neck VMAT audit had an agreement of À4%, À2%, À3%, and À3% for the TLD located in the superior-anterior, inferior-anterior, superior-posterior, and inferior-posterior primary PTV, respectively (tolerance: ≤7%). The TLDs in the secondary PTV showed a dose difference with calculation of À2% and À1% for the superior and inferior position, respectively. For the OAR, an agreement of À3% and À5% was found for the superior and inferior OAR, respectively. The cAS (7%(global)/5 mm) was 99% and 97% for the axial and the sagittal film plane, respectively (tolerance: ≥85%). All E2E audit measurements satisfied the IROC Houston's credentialing criteria. Table III gives an overview of the patient-specific QA results for the first patients of each new indication treated on the fast-rotating O-ring linac. Patient-specific QA for IMRT and VMAT had cAS (3%(local)/2 mm) above 96.5% and 93.9% (portal image dosimetry), 92.9% and 95.8% (diode array), 91.4% and 91.7% (film dosimetry), and point dose differences below 2.5% and 2.7%, respectively. All treatment plans had QA results within the action limits suggested by TG-218 40 (i.e., cAS ≥ 90% and point dose difference ≤3%). Out of the 7 IMRT plans and 19 VMAT plans selected for patient-specific QA, 2 IMRT plans and 11 VMAT plans had QA results within the tolerance levels suggested by TG-218 (i.e., cAS ≥ 95% and point dose difference ≤2%) for all QA measurements. Points that failed the c-criteria were located outside the target. All treatment plans that failed the TG-218 tolerance levels were inspected individually and deemed clinically acceptable.
3.F. Patient-specific quality assurance
DISCUSSION
This work reports on the validation of a fast-rotating O-ring dedicated IMRT/VMAT delivery system, the Varian Halcyon system. By default, the system is tuned with respect to a reference beam model and is delivered with a preconfigured TPS. However, limited information concerning the default performance of the system and the IMRT/ VMAT delivery quality is currently available in literature. Additionally, it is not yet known what validation tests should be performed in order to ascertain whether the installed system matches the reference beam model included in the TPS and satisfies the international commissioning criteria. 15, 16 In this work, we have opted to perform all the validation tests suggested by the AAPM MPPG 5.a guidelines 15 (i.e., basic photon beam model validation, 34 IMRT/VMAT validation, 16 E2E testing, external audits [17] [18] [19] and patient-specific QA 26 ). Medical Physics, 46 (1), January 2019
It was found that the measured single-layer MLC transmission (0.42 AE 0.01%) and DLG (0.27 AE 0.22 mm) of the system differed from the modeled values in the TPS (0.47% for the MLC transmission and 0.10 mm for the DLG). Note however, that the DLG measurements were subject to large uncertainty such that the modeled value lies within the uncertainty limits. More importantly, these differences had no major influence on the resulting dose accuracy as the TG-119 measurements (Section 3.C) and E2E measurements (Section 3.D) performed in this study showed good agreement The number of patient plans selected for patient-specific QA is given within brackets. The median value is given together with two quantiles (25% and 75%) between square brackets. For the rectum and the esophagus the minimum and maximum values are given due to the low number of patients (n rectum = 2 and n esophagus = 2) treated on the fast-rotating O-ring linac.
Indication
A1SL IC
Portal image dosimetry Diode array EBT3 film Point dose (%)
Rectum (2 33, 41 Hence, measuring the DLG allows to validate whether the MLC performance of the system is within the expected specifications (0.10 mm to 0.30 mm in this case) but does not necessarily suffice to validate the dosimetric performance of the modeled DLG in clinical practice.
The TG-119 test suite cases are designed to assess the overall accuracy of IMRT/VMAT and to explore the limitations of the system. 16 In this study, we found that the TG-119 confidence levels were not achieved for IMRT point dose measurements in both the target and the avoidance structure (Section 3.C). This failure of the recommended confidence levels is mainly attributed to the large dose differences observed for the IMRT point dose measurements of the C-shape hard test case (dose difference of 4.4% in the target and À5.7% in the avoidance structure). Radiochromic film measurements for the C-shape hard test case (Fig. 5 ) confirm these findings as points at the location of the IMRT point dose measurement failed the 3%(local)/ 3 mm c-criteria. Comparing these observations with respect to VMAT (dose difference of 1.9% in the target and À2.8% in the avoidance structure) indicate that IMRT had lower dosimetric performance with respect to VMAT for this worst-case scenario. Note that the TG-119 report affirms that the hard constraints for the C-shape test case are probably not achievable and are designed to test a system that is being pushed very hard. 16 When omitting the results for the C-shape hard test case, the calculated point dose confidence levels for IMRT become 4.1% for the target and 2.4% for the avoidance structure, both satisfying the TG-119 recommendations. 16 In this study, the Eclipse v15.1 TPS allowed for the field shaping to be performed by the distal leaves only while the proximal leaves serve as backup. The Eclipse v15.6 TPS, on the contrary, supports the field shaping to be performed by both leaf banks independently, allowing for finer shaping of the field apertures. This independent leaf motion increases the importance of accurate modeling of small beam apertures and MLC parameters, as the latter must be modeled for each bank individually. The influence of these MLC parameters need to be validated. Moreover, the additional degrees of freedom offered to the optimizer could result in more complex aperture shapes during IMRT and VMAT delivery. Both aspects could impact the treatment delivery quality and advocate further investigation.
Preconfigured systems will change the way on how we approach the subject of acceptance and commissioning of linacs. Due to the preconfigured TPS it may no longer be necessary, nor possible, for the user to fine-tune the beam model with respect to the measured data. Rather, the user should ascertain whether the installed system matches with the reference beam model included in the TPS and satisfies the commissioning criteria. 15, 16 Ideally, such a validation should be performed during acceptance testing as the user cannot modify the system independently from the manufacturer afterwards. Within this regard, one can ask whether the full-blown approach used in this study is necessary to ascertain the treatment delivery quality. It may well be that a reduced, standardized set of validation measurements is sufficient to approve the system for clinical treatments. Such a standardized set would allow for rapid assessment of the performance of the system and could be included within the acceptance testing. The answer to this question will depend on the amount of consistency that can be obtained by the manufacturer in reproducing the system with respect to the reference beam model. 42 With this report we want to initiate this investigation and offer reference information for other users to compare their results with.
CONCLUSION
The fast-rotating O-ring linac and its preconfigured TPS is compliant with the international commissioning guidelines of AAPM MPPG 5.a 15 and AAPM TG-119. 16 End-to-end measurements on heterogeneous anthropomorphic phantoms were within clinically acceptable tolerances. The IROC beam calibration audit had an agreement of 1% between measured and calculated dose in standard conditions. IROC Houston's E2E audits for both lung IMRT 17 and head and neck VMAT 18, 19 were within the credentialing criteria. All treatment plans selected for patient-specific QA had results within the actions limits specified by TG-218. 40 This work comprises the first extensive dataset reporting on the preconfigured fast-rotating O-ring linac, offering reference information for future users of the system.
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